Discover more insights into Pd L1 Treatment Pd L1 치료

Keywords frequently search together with Pd L1 Treatment Pd L1 치료

Narrow sentence examples with built-in keyword filters


Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma



Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies



Downregulating testosterone levels enhance immunotherapy efficiency



Inhibition of xCT Suppresses the Efficacy of Anti-PD-1/-L1 Melanoma Treatment through Exosomal PD-L1 Induced Macrophage M2 Polarization.



Soluble Programmed Death-Ligand 1 (sPD-L1) as a Novel Biomarker for the Combination of Anti-PD-L1 Antibody and Radiotherapy for Glioma Patients.



Optimizing the Treatment Schedule of Radiotherapy Combined With Anti-PD-1/PD-L1 Immunotherapy in Metastatic Cancers



Acquired resistance to PD-L1 inhibition is associated with an enhanced type I IFN-stimulated secretory program in tumor cells



Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell-Mediated Antitumor Immunity Through PD-L1.



Ultrafine Jujube Powder Enhances the Infiltration of Immune Cells during Anti-PD-L1 Treatment against Murine Colon Adenocarcinoma



Multi-omics consensus ensemble refines the classification of muscle-invasive bladder cancer with stratified prognosis, tumour microenvironment and distinct sensitivity to frontline therapies



Biomimetic black phosphorus quantum dots-based photothermal therapy combined with anti-PD-L1 treatment inhibits recurrence and metastasis in triple-negative breast cancer



A false alarm of COVID-19 pneumonia in lung cancer with anti-PD-1 related pneumonitis: a case report and review of the literature



The augment of regulatory T cells undermines the efficacy of anti-PD-L1 treatment in cervical cancer



PD-L1 induces macrophage polarization toward the M2 phenotype via Erk/Akt/mTOR.



SChLAP1 contributes to non-small cell lung cancer cell progression and immune evasion through regulating the AUF1/PD-L1 axis



Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC



Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8+ T Cell Response in Hepatocellular Carcinoma



Immune checkpoint inhibitors at any treatment line in advanced NSCLC: Real-world overall survival in a large Italian cohort.


More Pd L1 Treatment Pd L1 치료 sentence examples
10.1200/JCO.2021.39.15_SUPPL.E13593

Assessing the impact of anti-PD-1/PD-L1 inhibitors on cancer care health and budget in Ireland.



Abstract LB164: A novel glycomimetic compound (GMI-1757) with dual functional antagonism to E-selectin and galectin-3 attenuates fibrosis, facilitates mononuclear cell infiltration and optimizes anti-PD-L1 therapeutic activity in a pancreatic adenocarcinoma model



Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing



Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells



Comparative Impact of PD-1 and PD-L1 Inhibitors on Advanced Esophageal or Gastric/Gastroesophageal Junction Cancer Treatment: A Systematic Review and Meta-Analysis



Abstract 376: Prognostic significance of Glasgow prognostic score in NSCLC patients treated with immunotherapy after platinum-based cytotoxic chemotherapy



Peripheral CD4+ T cell signatures in predicting the responses to anti-PD-1/PD-L1 monotherapy for Chinese advanced non-small cell lung cancer.



Immunotherapy response modeling by ex-vivo organ culture for lung cancer



Immune checkpoint inhibitors and pre-existing antinuclear antibodies: the rheumatologist point of view



Immune subtyping for pancreatic cancer with implication in clinical outcomes and improving immunotherapy



Abstract LB157: Discovery and characterization of INCB106385: a novel A2A/A2Badenosine receptor antagonist, as a cancer immunotherapy


More Pd L1 Treatment Pd L1 치료 sentence examples
10.51620/0869-2084-2021-66-3-139-146

Prognostic significance of soluble forms of immune checkpoint PD-1/PDL1 receptor and ligand in blood plasma of gastric cancer patients.



Remodels the Immunosuppressive Tumor Microenvironment by Combination of Bacillus Calmette–Guérin and Anti-PD-L1 in an Orthotopic Triple-Negative Breast Cancer Mouse Model



Expression of p53 Protein Associates with Anti-PD-L1 Treatment Response on Human-Derived Xenograft Model of GATA3/CR5/6-Negative Recurrent Nonmuscular Invasive Bladder Urothelial Carcinoma



Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8+ T cell-mediated ferroptosis in castration-resistant prostate cancer



The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer



The knowns & unknowns of pulmonary toxicity following immune checkpoint inhibitor therapies: a narrative review.



Safety and Activity of Programmed Cell Death 1 Versus Programmed Cell Death Ligand 1 Inhibitors for Platinum-Resistant Urothelial Cancer: A Meta-Analysis of Published Clinical Trials



Case Report: Anlotinib Reverses Nivolumab Resistance in Advanced Primary Pulmonary Lymphoepithelioma-Like Carcinoma With FGFR3 Gene Amplification



Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1



Plasma cytokines interleukin-18 and C-X-C motif chemokine ligand 10 are indicative of the anti-programmed cell death protein-1 treatment response in lung cancer patients.


More Pd L1 Treatment Pd L1 치료 sentence examples
10.1200/JCO.2021.39.15_SUPPL.TPS2658

A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced-stage solid tumors (ACRONYM: GDFATHER).



Multi-Parameter Quantitative Imaging of Tumor Microenvironments Reveals Perivascular Immune Niches Associated with Anti-Tumor Immunity


More Pd L1 Treatment Pd L1 치료 sentence examples
10.1200/JCO.2021.39.15_SUPPL.2604

YAP1 mutation as a novel predictor of response to anti-PD-1/PD-L1 treatment in pan-cancers.



Therapeutic anti-PD-L1 antibody affects ESCRT-mediated functions in cells expressing oncogenic EGFR


More Pd L1 Treatment Pd L1 치료 sentence examples
10.1200/JCO.2021.39.15_SUPPL.TPS2671

Trials in progress: A phase 1, open-label, dose-escalation, pharmacokinetic, safety and tolerability study of the selective TAM kinase inhibitor PF-07265807 in patients with advanced or metastatic solid tumors.



Bullous pemphigoid secondary to bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1



Significance of Glasgow prognostic scores in NSCLC patients treated with immunotherapy after platinum-based cytotoxic chemotherapy



CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation



γδ T Cells in Merkel Cell Carcinomas Have a Proinflammatory Profile Prognostic of Patient Survival


More Pd L1 Treatment Pd L1 치료 sentence examples
10.1016/j.oraloncology.2021.105472

TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells.



Tet2 Inactivation Enhances the Antitumor Activity of Tumor-Infiltrating Lymphocytes


Learn more from Pd L1 Treatment Pd L1 치료

Pd L1 Treatment Pd L1 치료


Pd L1 Treatment Pd L1 치료
Encyclopedia 백과사전